Recent Study Successes

SIV to FPI timelines

SIV-to-FPI timelines can vary significantly across sites and studies and remain an important indicator of overall site performance and operational readiness. At US CTS, our internal aspirational goal is to achieve an SIV-to-FPI interval of 7 days. In a recent Stage IV oncology study, the US CTS Research Site’s team in Tbilisi established the same target for ourselves.

In practice, however, the timeline is influenced by several operational factors. Although the SIV took place on April 20, 2026 as planned, the laboratory kits were delayed and did not arrive until April 28, at which point the site was formally activated. Consequently, patient screening logistics had to be re-coordinated among the US CTS Research Site’s team, hospital laboratories, couriers, and, importantly, the patient, who happened to reside outside of Tbilisi.

Ultimately, the first patient was screened on Saturday, May 9, 2026, representing the earliest operationally feasible date for all parties involved. This was also a milestone for the study as it was the first patient screened in the country.

While we continue to target a 7-day SIV-to-FPI interval whenever possible, this example illustrates how timelines may occasionally extend due to circumstances beyond US CTS’ control. Nevertheless, regardless of the challenges encountered, you can count on US CTS to make every effort to minimize the SIV-to-FPI timeline.

The study remains ongoing, with several additional patients now screened and successfully enrolled.